INTRODUCTION
============

Although blood transfusion is an important life-saving procedure performed according to level of anemia in both patients with malignancies and those with various underlying benign conditions, it carries a significant risk for unfavorable outcomes, including incompatibility, possibility for infection transmission, coagulopathy, and allergic reaction \[[@B1][@B2]\]. In particular, curative surgery for malignancy is always associated with the risk for massive bleeding; therefore, the probability of blood transfusion may also increase. However, the results of several meta-analyses have consistently indicated the existence of a negative association between perioperative blood transfusion (PBT) and oncologic outcomes, including tumor recurrence and survival, in surgically treated patients with various malignancies, including stomach, lung, liver, and colorectal cancer \[[@B3][@B4][@B5][@B6][@B7]\]. Although the mechanism underlying this unfavorable association is not fully understood, it is hypothesized that immune modulation and inflammatory responses caused by PBT adversely affect oncologic outcomes after radical surgery for cancer \[[@B1][@B2][@B8]\].

Several trials have also evaluated the effect of PBT on oncologic outcomes after radical surgery in the field of urologic oncology, including bladder, prostate, and kidney cancer \[[@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17]\]. Nephrectomy using the radical or partial approach is the standard treatment for nonmetastatic renal cell carcinoma (RCC). Previous reports have shown that rates of PBT range from 10% to 20% and that PBT is associated with worse postoperative outcomes, such as higher recurrence and higher risk for death in patients with localized RCC who underwent nephrectomy \[[@B14][@B15][@B16][@B17]\]. However, evidence is scarce regarding the prognostic role of PBT in the Asian RCC population.

In the current study, we aimed to verify the prognostic role of PBT in terms of oncologic outcomes and to elucidate the factors related to the receipt of PBT in a large single-center cohort consisting of Korean RCC patients treated with curative surgery.

MATERIALS AND METHODS
=====================

1. Study population
-------------------

This study design and the use of patients\' information stored in the hospital database were approved by the Institutional Review Board (IRB) at Seoul National University Hospital. The approval number is H-1407-197-600. We received exemption from getting informed consent by the IRB because the present study was a retrospective study, personal identifiers were completely removed, and the data were analyzed anonymously. Our study was conducted according to the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

After IRB approval from Seoul National University Hospital, we reviewed the nephrectomy database comprising 2,538 patients who underwent radical or partial nephrectomy for a renal mass from 2000 to 2014. Of these patients, those with incomplete information about PBT, insufficient data on patient demographics, pathologies other than RCC, or metastatic disease at the time of surgery were excluded from the study. Finally, 2,329 patients with nonmetastatic RCC were included in our analysis.

2. Acquisition and definition of data
-------------------------------------

Radical or partial nephrectomy was performed by several surgeons during the study period. The following preoperative clinical factors were considered: presence or absence of symptomatic presentation, age at surgery, sex, body mass index (BMI; defined as the body weight \[in kilograms\] divided by the square of height \[in meters\]), preoperative serum hemoglobin (Hb) and creatinine (Cr) level, smoking status, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension (HTN), diabetes mellitus (DM), and end-stage renal disease (ESRD). Surgery-related parameters included surgical approach (laparoscopic: transperitoneal, retroperitoneal, or hand-assisted/open/robot-assisted), surgical method (radical or partial), operation time, and estimated blood loss (EBL). Tumor-related factors included histologic subtype (clear cell vs. non-clear cell), tumor stage (pT1/T2/T3/T4), Fuhrman nuclear grade (Gr1-2/3/4), tumor size, pseudosarcomatous component, tumor necrosis, and nodal status (pN0/N1/Nx). All pathologic specimens were processed in accordance with institutional standard procedures and were evaluated by expert genitourinary pathologists depending on a standardized reporting protocol. PBT only included transfusion of allogeneic packed red blood cells (pRBCs) during nephrectomy or within the preoperative or postoperative hospitalization period. Because there were no unified institutional criteria with regard to the thresholds for PBT, transfusion was determined at the discretion of the surgeons depending on biomarkers such as patient\'s anemia level and blood pressure.

3. Follow-up protocol
---------------------

After surgery, patients were usually followed up every 6 months for the first year and then yearly for 5 years with routine blood examination and imaging studies (chest roentgenography or computed tomography \[CT\] and abdominopelvic CT scan or magnetic resonance imaging). The endpoints of this study included recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). RFS was defined as the duration from the time of surgery to the first time of tumor recurrence. The duration of CSS or OS was calculated as the period from the date of surgery to the date of RCC-related or any-cause death, respectively. Patients who lived with or without RCC were censored from the survival analyses. The date of death was identified by reviewing medical charts or from the annual census of the Korea National Statistical Office. Reason of death was confirmed by the physicians in charge and from death certificates.

4. Statistical analyses
-----------------------

The included parameters were compared between transfused and nontransfused patients using chi-squared or Fisher\'s exact tests for categorical variables and the Mann--Whitney test for continuous variables. Continuous variables are expressed as the median and interquartile range (IQR); categorical variables are denoted as absolute numbers and relative percentages. The preoperative factors related to the receipt of PBT were evaluated using univariate and multivariable logistic regression analysis. The estimation and comparison of survival outcomes according to the receipt of PBT was assessed by using the Kaplan--Meier method with a log-rank test. Finally, the impact of PBT on each survival outcome was evaluated using multivariable Cox proportional-hazards models. All analyses were performed with IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY, USA), and two-sided p-values of \<0.05 were considered to be statistically significant.

RESULTS
=======

1. Baseline characteristics of the study cohort
-----------------------------------------------

The characteristics of the study cohort and comparative results for each parameter according to the receipt of PBT are listed in [Table 1](#T1){ref-type="table"}. Among all patients, PBT was performed in 275 patients (11.8%) with a median unit of 3 pRBCs (IQR, 2--5). Compared with the non-PBT group, those who received PBT were more likely to be older, to be female, and to have more frequent symptomatic presentation, lower BMI, lower preoperative Hb level, higher preoperative Cr level, worse ECOG performance status, higher frequency of HTN, higher frequency of DM, higher frequency of ESRD, higher percentage of open and radical approach, longer operative time, more advanced tumor stage, higher nuclear grade, larger tumor size, and more frequent pseudosarcomatous component, tumor necrosis, and nodal invasion (all p-values \<0.05). Moreover, the PBT group showed a higher EBL (median, 700 mL; IQR, 300--1,200 mL) compared with the non-PBT group (median, 200 mL; IQR, 100--300 mL; p\<0.001). There was a significant difference in the median follow-up duration between the PBT and non-PBT groups (35 vs. 47 months; p\<0.001). Univariate and multivariate logistic regression analysis demonstrated that symptomatic presentation, advanced age at surgery, higher preoperative serum Cr, and lower preoperative Hb level were independent preoperative risk factors for PBT (all p\<0.05) ([Table 2](#T2){ref-type="table"}).

2. Impact of PBT on survival outcomes after surgery for RCC
-----------------------------------------------------------

Postoperative recurrence was observed in 235 patients (10.1%), with a median time to recurrence of 39 months (IQR, 17--60 months). A total of 228 patients (9.8%) died of any causes, within a median follow-up period of 45 months (IQR, 24--74), and 150 deaths (6.4%) among these were directly associated with RCC ([Table 1](#T1){ref-type="table"}). Kaplan--Meier analysis using the log-rank test revealed that the PBT group had worse 5-year RFS (65.1% vs. 91.2%, p\<0.001), OS (71.4% vs. 92.8%, p\<0.001), and CSS (74.0% vs. 95.5%, p\<0.001) compared with the non-PBT group ([Fig. 1](#F1){ref-type="fig"}). However, in the multivariable Cox regression analyses incorporating other clinicopathologic variables in the entire study cohort, PBT was not a significant predictor of RFS, OS, or CSS ([Table 3](#T3){ref-type="table"}). Multivariable Cox proportional-hazards analyses of the PBT group alone (n=275) showed that an increased number of pRBC units was an independent predictor of worse OS (hazard ratio \[HR\], 1.043; 95% confidence interval \[CI\], 1.008--1.078; p=0.016) and CSS (HR, 1.066; 95% CI, 1.033--1.100; p\<0.001), but not of RFS (HR, 0.986; 95% CI, 0.936--1.038; p=0.587) ([Table 4](#T4){ref-type="table"}).

3. Subgroup analyses
--------------------

Additional subgroup analyses were conducted by RCC histologic subtype (clear cell versus non-clear-cell RCC). Kaplan--Meier plots with the log-rank test suggested there were no significant differences in RFS, OS, and CSS regardless of RCC histologic subtype ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). In addition, when multivariable Cox regression analyses were conducted to identify the predictors of each survival outcome in each RCC histology group, PBT was not a significant predictor of survival outcomes in either group ([Supplementary Tables 1](#S2){ref-type="supplementary-material"} and [2](#S3){ref-type="supplementary-material"}). Tumor diameter in clear cell RCC ([Supplementary Table 1](#S2){ref-type="supplementary-material"}) and lymph node involvement (pN1) in the non-clear-cell RCC group ([Supplementary Table 2](#S3){ref-type="supplementary-material"}) were significant predictors of all survival outcomes.

DISCUSSION
==========

Generally, the prognosis, including recurrence and mortality, of cancer patients is primarily determined by tumor-related factors such as tumor stage, nuclear grade, tumor size, and histologic subtype \[[@B18][@B19]\]. Other than these factors, several clinical factors have also been suggested in association with cancer prognosis \[[@B18][@B19]\]. Among these, blood transfusion using allogeneic pRBC units has been extensively examined in various types of cancer, and these studies have suggested a deleterious effect on prognosis \[[@B3][@B4][@B5][@B6][@B7]\]. In addition to the combined impact of surgery and anesthesia-induced immunosuppression, administration of blood products can further aggravate the immunosuppressive status of cancer patients, resulting in transfusion-related immune modulation (TRIM). Although the mechanism has not been fully clarified, the effects of TRIM may be mediated by the suppression of cytotoxic cell and monocyte activity, an increase in suppressor T-cell activity, and the release of a variety of immunosuppressive and inflammatory cytokines, such as prostaglandins, interleukins, interferon-gamma, and transforming growth factor-beta 1, which are induced by various antigens, such as white blood cells and soluble human leukocyte antigen peptides included in allogeneic blood products \[[@B2][@B8]\]. These immunosuppressive and inflammatory responses caused by TRIM are thought to promote tumor growth and metastasis and adversely affect the prognosis of cancer patients \[[@B2][@B8]\].

The prognostic role of PBT has also been investigated in the field of urologic oncology, including RCC \[[@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17]\]. Several retrospective trials demonstrated that in bladder cancer patients treated with radical cystectomy, PBT is associated with increased overall mortality and morbidity \[[@B9][@B11]\], and in prostate cancer patients undergoing radical prostatectomy, whereas allogeneic PBT is a significant predictor of worse postoperative biochemical recurrence and survival outcomes, autologous PBT is not \[[@B12]\]. Recent meta-analyses confirmed these associations of PBT with adverse oncologic outcomes in bladder and prostate cancer patients treated with radical surgery \[[@B10][@B13]\]. In the case of RCC, several retrospective studies have reported a negative relationship between PBT and oncologic outcomes. Linder et al. \[[@B14]\] reported that in 2,318 patients with localized RCC who underwent curative nephrectomy including 498 transfused patients (21%), allogeneic PBT was a significant predictor of increased risk of overall mortality, and in those who received PBT alone, an increase in the number of transfused pRBC units was independently associated with worse OS. Tsivian et al. \[[@B15]\] also reported that allogeneic PBT was associated with approximately a twofold increase in the risk of metastatic progression, all-cause mortality, and RCC-specific mortality. One retrospective analysis that included 1,168 RCC patients treated with nephrectomy reported that when analysis was conducted according to the timing of blood transfusion (117, intraoperative; 81, postoperative), intraoperative allogeneic blood transfusion, but not postoperative blood transfusion, was significantly associated with increased risks for postoperative cancer recurrence and mortality \[[@B16]\]. In addition, a recent meta-analysis noted that PBT was a significant predictor of worse OS in patients with nonmetastatic RCC who underwent nephrectomy \[[@B17]\].

This consistent negative association of PBT and RCC-related oncologic outcomes was identified in the current study In our study, PBT of allogeneic pRBC in RCC patients was significantly associated with adverse clinical and pathologic features, such as older age, worse ECOG performance status, more advanced tumor stage, higher nuclear grade, larger tumor size, more frequent pseudosarcomatous component, tumor necrosis, and nodal invasion ([Table 1](#T1){ref-type="table"}). This result agrees with the results of previous reports \[[@B14][@B15]\]. However, although PBT was a significant predictor of worse survival outcomes in the Kaplan--Meier analysis ([Fig. 1](#F1){ref-type="fig"}), the statistical significance of this association was not confirmed in the multivariable Cox regression analysis with adjustment for well-known prognostic factors of RCC ([Table 3](#T3){ref-type="table"}). This might be the result of confounding effects due to the prognostic factors more frequently included in the PBT group. To avoid these confounding effects, we conducted an analysis that included only RCC patients receiving PBT. That analysis demonstrated that an increased number of transfused pRBC units was significantly associated with worse OS and CSS. This negative relationship between transfusion volume and cancer prognosis was also identified previously \[[@B9][@B14]\]. Therefore, we suggest that for patients with a higher likelihood of receiving blood transfusion, such as those with symptomatic presentations, advanced age, and lower preoperative Hb levels, efforts are required to reduce allogeneic PBT, including the use of preoperative autologous blood collection with or without acute normovolemic hemodilution technique and its intraoperative transfusion, autologous blood transfusion via intraoperative cell salvage techniques, and recombinant human erythropoietin, to improve postoperative survival outcomes \[[@B2][@B20][@B21]\].

This study had some limitations as follows. First, owing to the retrospective study design, a selection bias is likely. Thus, unidentified confounding factors might have affected our findings. For instance, we did not investigate or include comorbidities other than HTN and DM, such as cerebrovascular or cardiovascular disease, which might adversely affect survival outcomes. Second, as mentioned earlier, because PBT was administered at the discretion of each surgeon without specific criteria, it is possible that unnecessary PBT might have been performed, with detrimental effects on clinical outcomes. Third, only allogeneic pRBC was considered as a blood product for PBT. Therefore, we did not evaluate the effect of autologous blood transfusion and other blood products, such as fresh-frozen plasma or platelet concentrates on oncologic outcomes. However, according to previous reports, there is currently no clear evidence that autologous blood transfusion has an advantage over allogeneic blood transfusion in terms of cancer prognosis or regarding the influence of other blood products on cancer prognosis \[[@B2]\]. Fourth, blood transfusion was considered as perioperative administration and was not divided into preoperative, intraoperative, and postoperative administration owing to the retrospective nature of the study. If analyzed according to the timing of transfusion, the prognostic role of blood transfusion might be different, as reported in the previous studies \[[@B16][@B22]\]. Last, although the number of enrolled patients in the current study was larger than in previous retrospective studies, the prognostic impact of allogeneic PBT on RCC-related outcomes derived from this study should be explored further through well-designed prospective clinical trials.

CONCLUSIONS
===========

Our data imply that PBT may have an adverse effect on RFS, OS, and CSS in patients with nonmetastatic RCC treated with curative surgery, although a significant correlation was not identified in the multivariable analyses. Particularly, an increase of pRBC units in transfused patients may be problematic considering the high possibility of worse OS and CSS. Therefore, for RCC patients who are likely to receive PBT, such as those with symptomatic presentations, older age, lower preoperative Hb, and high preoperative Cr level, efforts to limit the overuse of PBT seem imperative to improve postoperative survival.
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###### Supplementary Fig. 1.

Kaplan--Meier curves for each survival outcome according to renal cell carcinoma (RCC) histologic subtype (clear cell RCC versus non-clear-cell RCC) in the entire study cohort. (A) Recurrence-free survival. (B) Overall survival. (C) Cancer-specific survival.

###### Supplementary Table 1

Multivariable Cox proportional hazard models for RFS, OS, and CSS in clear cell RCC patients (n=1,887)

###### Supplementary Table 2

Multivariable Cox proportional hazard models for RFS, OS, and CSS in non-clear cell RCC patients (n=442)

![Kaplan--Meier curves for each survival outcome according to perioperative blood transfusion (PBT) in the entire study cohort. (A) Recurrence-free survival. (B) Overall survival. (C) Cancer-specific survival.](icu-61-136-g001){#F1}

###### Patient characteristics of the study cohort and comparative analysis results according to receipt of PBT

![](icu-61-136-i001)

  Variable                                 Total (n=2,329)     Non-PBT (n=2,054, 88.2%)   PBT (n=275, 11.8%)   p-value
  ---------------------------------------- ------------------- -------------------------- -------------------- ---------
  Preoperative clinical parameters                                                                             
   Symptomatic presentation                                                                                    \<0.001
    Asymptomatic                           1,856 (79.7)        1,693 (82.4)               163 (59.3)           
    Symptomatic                            473 (20.3)          361 (17.6)                 112 (40.7)           
   Age at surgery (y)                      56 (47--66)         55 (47--65)                62 (50--69)          \<0.001
   Sex                                                                                                         0.006
    Male                                   1,646 (70.7)        1,471 (71.6)               175 (63.6)           
    Female                                 683 (29.3)          583 (28.4)                 100 (36.4)           
   Body mass index (kg/m^2^)               24.4 (22.5--26.5)   24.5 (22.6--26.6)          23.5 (21.9--25.6)    \<0.001
   Preoperative hemoglobin (g/dL)          14.0 (12.7--15.1)   14.1 (12.0--15.2)          11.8 (10.3--13.6)    \<0.001
   Preoperative serum creatinine (mg/dL)   1.00 (0.84--1.10)   1.00 (0.84--1.10)          1.03 (0.86--1.30)    \<0.001
   Smoking status at diagnosis                                                                                 0.225
    No                                     1,957 (84.0)        1,719 (83.7)               238 (86.5)           
    Yes                                    372 (16.0)          335 (16.3)                 37 (13.5)            
   ECOG performance status                                                                                     \<0.001
    0                                      1,737 (74.6)        1,562 (76.0)               175 (63.6)           
    1                                      495 (21.3)          421 (20.5)                 74 (26.9)            
    2                                      78 (3.3)            59 (2.9)                   19 (6.9)             
    3                                      12 (0.5)            7 (0.3)                    5 (1.8)              
    Missing/unknown                        7 (0.3)             5 (0.2)                    2 (0.7)              
   Hypertension                                                                                                \<0.001
    No                                     1,392 (59.8)        1,262 (61.4)               130 (47.3)           
    Yes                                    937 (40.2)          792 (38.6)                 145 (52.7)           
   Diabetes mellitus                                                                                           \<0.001
    No                                     2,007 (86.2)        1,796 (87.4)               211 (76.7)           
    Yes                                    322 (13.8)          258 (12.6)                 64 (23.3)            
   ESRD                                                                                                        \<0.001
    No                                     2,269 (97.4)        2,014 (98.1)               255 (92.7)           
    Yes                                    60 (2.6)            40 (1.9)                   20 (7.3)             
  Intraoperative parameters                                                                                    
   Surgical approach I                                                                                         \<0.001
    Laparoscopic, transperitoneal          377 (16.2)          357 (17.4)                 20 (7.3)             
    Laparoscopic retroperitoneal           25 (1.1)            23 (1.1)                   2 (0.7)              
    Hand-assisted laparoscopic             120 (5.2)           108 (5.3)                  12 (4.4)             
    Open                                   1,629 (69.9)        1,397 (68.0)               232 (84.4)           
    Robot-assisted                         178 (7.6)           169 (8.2)                  9 (3.3)              
   Surgical approach II                                                                                        \<0.001
    Radical                                1,160 (49.8)        969 (47.2)                 191 (69.5)           
    Partial                                1,140 (48.9)        1,061 (51.7)               79 (28.7)            
    Partial to radical conversion          29 (1.2)            24 (1.2)                   5 (1.8)              
   Operation time (min)                    150 (115--185)      145 (115--180)             180 (125--235)       \<0.001
   Estimated blood loss (mL)               200 (100--350)      200 (100--300)             700 (300--1,200)     \<0.001
  Pathologic parameters                                                                                        
   Histological subtype                                                                                        0.645
    ccRCC                                  1,887 (81.0)        1,667 (81.2)               220 (80.0)           
    Non-ccRCC                              442 (19.0)          387 (18.8)                 55 (20.0)            
   Pathologic tumor stage                                                                                      \<0.001
    pT1                                    1,870 (80.3)        1,724 (83.9)               146 (53.1)           
    pT2                                    194 (8.3)           150 (7.3)                  44 (16.0)            
    pT3                                    257 (11.0)          173 (8.4)                  84 (30.5)            
    pT4                                    8 (0.3)             7 (0.3)                    1 (0.4)              
   Fuhrmann nuclear grade                                                                                      \<0.001
    Gr1                                    157 (6.7)           146 (7.1)                  11 (4.0)             
    Gr2                                    1,217 (52.3)        1,118 (54.4)               99 (36.0)            
    Gr3                                    837 (35.9)          714 (34.8)                 123 (44.7)           
    Gr4                                    109 (4.7)           67 (3.3)                   42 (15.3)            
    Missing/unknown                        9 (0.4)             9 (0.4)                    0 (0.0)              
   Tumor size (cm)                         3.4 (2.0--5.5)      3.2 (2.0--5.0)             5.6 (3.0--10.0)      \<0.001
   Pseudosarcomatous component                                                                                 0.014
    Absent                                 2,295 (98.5)        2,029 (98.8)               266 (96.7)           
    Present                                34 (1.5)            25 (1.2)                   9 (3.3)              
   Tumor necrosis                                                                                              \<0.001
    Absent                                 1,668 (71.6)        1,528 (74.4)               140 (50.9)           
    Present                                661 (28.4)          526 (25.6)                 135 (49.1)           
   Pathologic nodal stage                                                                                      \<0.001
    pN0                                    249 (10.7)          185 (9.0)                  64 (23.3)            
    pN1                                    29 (1.2)            19 (0.9)                   10 (3.6)             
    pNx                                    2,051 (88.1)        1,850 (90.1)               201 (73.1)           
  Postoperative follow-up parameters                                                                           
   Time to recurrence (mo)                 39 (17--60)         41 (18--60)                22 (6--53)           \<0.001
   Recurrence result                                                                                           \<0.001
    No recurrence                          2,094 (89.9)        1,895 (92.3)               199 (72.4)           
    Recurrence                             235 (10.1)          159 (7.7)                  76 (27.6)            
   Median follow-up duration               45 (24--74)         47 (25--75)                35 (16--68)          \<0.001
   Overall survival result                                                                                     \<0.001
    Alive                                  2,101 (90.2)        1,902 (92.6)               199 (72.4)           
    All-cause death                        228 (9.8)           152 (7.4)                  76 (27.6)            
   CSS result                                                                                                  \<0.001
    Alive or other cause death             2,179 (93.6)        1,965 (95.7)               214 (77.8)           
    Cancer-specific death                  150 (6.4)           89 (4.3)                   61 (22.2)            

Values are presented as number (%) or median (interquartile range).

PBT, perioperative blood transfusion; ECOG, Eastern Cooperative Oncology Group; ESRD, end-stage renal disease; ccRCC, clear cell renal cell carcinoma; CSS, cancer-specific survival.

###### Univariate and multivariable logistic regression analyses assessing preoperative risk factors for the receipt of PBT
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  Variable                                     Univariate analysis     Multivariable analysis                          
  -------------------------------------------- ----------------------- ------------------------ ---------------------- ---------
  Symptomatic presentation (no vs. yes)        3.222 (2.470--4.205)    \<0.001                  2.716 (2.018--3.656)   \<0.001
  Sex (male vs. female)                        1.442 (1.108--1.877)    0.007                    0.818 (0.598--1.119)   0.208
  Age (continuous)                             1.029 (1.018--1.040)    \<0.001                  1.017 (1.006--1.030)   0.004
  Body mass index (continuous)                 0.931 (0.893--0.971)    0.001                    0.995 (0.949--1.043)   0.833
  ECOG (ref. 0)                                                                                                        
   1                                           1.569 (1.171--2.102)    0.003                    1.437 (1.038--1.989)   0.029
   2                                           2.874 (1.675--4.933)    \<0.001                  1.547 (0.828--2.891)   0.171
   3                                           6.376 (2.002--20.301)   0.002                    2.630 (0.705--9.803)   0.150
  Hypertension (no vs. yes)                    1.777 (1.380--2.289)    \<0.001                  1.193 (0.862--1.650)   0.287
  Diabetes mellitus (no vs. yes)               2.111 (1.551--2.875)    \<0.001                  1.360 (0.952--1.944)   0.091
  ESRD (no vs. yes)                            3.949 (2.273--6.861)    \<0.001                                         
  Preoperative serum creatinine (continuous)   1.231 (1.150--1.318)    \<0.001                  1.311 (1.114--1.542)   0.001
  Preoperative hemoglobin (continuous)         0.590 (0.549--0.634)    \<0.001                  0.629 (0.583--0.679)   \<0.001

PBT, perioperative blood transfusion; OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ESRD, end-stage renal disease.

###### Multivariable Cox proportional hazard models for RFS, OS, and CSS in the entire study cohort (n=2,329)
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  Variable                                    RFS                    OS        CSS                                                       
  ------------------------------------------- ---------------------- --------- ----------------------- --------- ----------------------- ---------
  Clinical parameters                                                                                                                    
   Symptomatic presentation (no vs. yes)      1.385 (1.031--1.864)   0.031     1.733 (1.284--2.339)    \<0.001   1.870 (1.293--2.703)    0.001
   Age (continuous)                           1.004 (0.992--1.016)   0.505     1.049 (1.036--1.062)    \<0.001   1.027 (1.010--1.043)    0.001
   Body mass index (continuous)               0.931 (0.890--0.974)   0.002     0.952 (0.910--0.996)    0.033     0.910 (0.857--0.966)    0.002
   ECOG performance status (ref. 0)                                                                                                      
    1                                         1.392 (1.040--1.864)   0.026     1.383 (1.028--1.859)    0.032     1.301 (0.896--1.889)    0.166
    2                                         1.931 (1.094--3.410)   0.023     1.974 (1.196--3.258)    0.008     1.354 (0.637--2.881)    0.431
    3                                         2.875 (0.903--9.155)   0.074     4.099 (1.474--11.398)   0.007     3.609 (0.849--15.346)   0.082
   Hypertension (no vs. yes)                  1.330 (1.006--1.759)   0.045     1.145 (0.839--1.564)    0.393     1.524 (1.042--2.227)    0.030
   Diabetes mellitus (no vs. yes)             1.461 (1.033--2.066)   0.032     1.806 (1.315--2.481)    \<0.001   2.114 (1.423--3.141)    \<0.001
   Preoperative hemoglobin (continuous)       0.966 (0.903--1.033)   0.313     0.910 (0.853--0.970)    0.004     0.958 (0.882--1.039)    0.300
   Receipt of PBT (no vs. yes)                1.193 (0.842--1.691)   0.321     1.229 (0.862--1.754)    0.255     1.139 (0.744--1.745)    0.550
  Pathologic parameters                                                                                                                  
   Maximal tumor diameter (continuous)        1.131 (1.083--1.181)   \<0.001   1.176 (1.119--1.236)    \<0.001   1.202 (1.140--1.268)    \<0.001
   Pathologic tumor stage (ref. pT1)                                                                                                     
    pT2                                       1.714 (1.099--2.674)   0.017     0.783 (0.478--1.282)    0.331     1.070 (0.597--1.916)    0.820
    pT3                                       3.604 (2.450--5.303)   \<0.001   1.585 (1.054--2.384)    0.027     2.569 (1.565--4.216)    \<0.001
    pT4                                       2.705 (0.989--7.403)   0.053     2.835 (1.100--7.310)    0.031     2.268 (0.790--6.516)    0.128
   Fuhrmann nuclear grade (ref. 1--2)                                                                                                    
    3                                         2.007 (1.450--2.779)   \<0.001   1.120 (0.817--1.536)    0.482     1.700 (1.115--2.591)    0.014
    4                                         2.790 (1.787--4.357)   \<0.001   1.074 (0.636--1.813)    0.791     1.940 (1.064--3.536)    0.031
   Pseudosarcomatous component (no vs. yes)   0.867 (0.456--1.648)   0.663     1.759 (0.926--3.344)    0.085     1.763 (0.917--3.388)    0.089
   Tumor necrosis (no vs. yes)                1.509 (1.135--2.007)   0.005     1.138 (0.842--1.538)    0.400     1.340 (0.919--1.953)    0.128
   pN1                                        3.370 (1.907--5.957)   \<0.001   4.515 (2.503--8.144)    \<0.001   4.454 (2.342--8.470)    \<0.001

RFS, recurrence-free survival; OS, overall survival; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PBT, perioperative blood transfusion.

###### Multivariable Cox proportional hazard models for RFS, OS, and CSS in patients receiving PBT (n=275)

![](icu-61-136-i004)

  Variable                                    RFS                     OS        CSS                                                       
  ------------------------------------------- ----------------------- --------- ----------------------- --------- ----------------------- ---------
  Clinical parameters                                                                                                                     
   Symptomatic presentation (no vs. yes)      1.517 (0.865--2.661)    0.146     1.935 (1.144--3.274)    0.014     2.632 (1.390--4.983)    0.003
   Age (continuous)                           1.012 (0.989--1.034)    0.311     1.039 (1.018--1.061)    \<0.001   1.025 (1.000--1.050)    0.050
   Body mass index (continuous)               0.933 (0.846--1.028)    0.162     0.918 (0.850--0.992)    0.031     0.920 (0.843--1.004)    0.062
   ECOG performance status (ref. 0)                                                                                                       
    1                                         1.984 (1.198--3.287)    0.001     1.857 (1.059--3.255)    0.031     2.324 (1.291--4.185)    0.005
    2                                         1.563 (0.681--3.586)    0.292     2.008 (0.844--4.775)    0.115     1.528 (0.597--3.906)    0.376
    3                                         N/A                     N/A       1.110 (0.135--9.141)    0.923     2.705 (0.345--21.187)   0.343
   Hypertension (no vs. yes)                  1.187 (0.678--2.078)    0.549     1.012 (0.558--1.834)    0.970     0.873 (0.447--1.704)    0.691
   Diabetes mellitus (no vs. yes)             0.835 (0.410--1.700)    0.619     1.087 (0.595--1.985)    0.787     0.859 (0.414--1.779)    0.682
   Preoperative hemoglobin (continuous)       0.905 (0.820--0.999)    0.048     0.950 (0.849--1.064)    0.377     0.951 (0.840--1.078)    0.433
   Number of units transfused (continuous)    0.986 (0.936--1.038)    0.587     1.043 (1.008--1.078)    0.016     1.066 (1.033--1.100)    \<0.001
  Pathologic parameters                                                                                                                   
   Maximal tumor diameter (continuous)        1.106 (1.035--1.182)    0.003     1.127 (1.050--1.210)    0.001     1.091 (1.013--1.176)    0.022
   Pathologic tumor stage (ref. pT1)                                                                                                      
    pT2                                       1.619 (0.643--4.077)    0.307     0.369 (0.147--0.923)    0.033     0.506 (0.183--1.400)    0.189
    pT3                                       4.383 (1.911--10.051)   \<0.001   1.153 (0.596--2.231)    0.672     1.360 (0.615--3.007)    0.447
    pT4                                       9.770 (0.998--95.636)   0.050     1.760 (0.205--15.101)   0.606     2.784 (0.307--25.247)   0.363
   Fuhrmann nuclear grade (ref. 1--2)                                                                                                     
    3                                         1.599 (0.762--3.359)    0.215     1.524 (0.737--3.149)    0.255     1.668 (0.673--4.131)    0.269
    4                                         1.797 (0.747--4.324)    0.191     1.486 (0.622--3.552)    0.373     1.688 (0.604--4.716)    0.318
   Pseudosarcomatous component (no vs. yes)   0.183 (0.040--0.839)    0.029     1.394 (0.421--4.614)    0.586     1.558 (0.457--5.310)    0.479
   Tumor necrosis (no vs. yes)                1.688 (1.000--2.851)    0.050     1.444 (0.808--2.580)    0.214     2.288 (1.164--4.500)    0.016
   pN1                                        4.993 (1.937--12.868)   0.001     2.049 (0.758--5.541)    0.158     1.423 (0.473--4.281)    0.530

RFS, recurrence-free survival; OS, overall survival; CSS, cancer-specific survival; PBT, perioperative blood transfusion; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.
